Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Alexandre Doussot

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0543-1793; OpenAlex author ID A5024506859. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
65
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
  2. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  3. Comment on: local control and survival after induction chemotherapy and ablative radiation versus resection for pancreatic ductal adenocarcinoma with vascular … First author DOI 10.21037/hbsn-21-336↗
  4. Pancreatic ductal adenocarcinoma and paraaortic lymph nodes metastases: The accuracy of intraoperative frozen section. Co-author DOI 10.1016/j.pan.2019.05.465↗
  5. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancrea… Co-author DOI 10.1016/j.hpb.2017.12.010↗
  6. Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Co-author DOI 10.1245/s10434-017-6323-3↗
  7. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Co-author DOI 10.1038/ncb3169↗
  8. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-015-4647-4↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pauline Georges · 2 shared papers, 2021–2025 · strength 0.44
  2. Mehdi El Amrani · 2 shared papers, 2022–2025 · strength 0.26
  3. Stéphanie Truant · 2 shared papers, 2022–2025 · strength 0.26
  4. Olivier Facy · 2 shared papers, 2019–2025 · strength 0.26
  5. William R. Jarnagin · 4 shared papers, 2015–2018 · strength 0.21
  6. T. Peter Kingham · 3 shared papers, 2015–2018 · strength 0.18
  7. Michael Ian D'Angelica · 3 shared papers, 2015–2018 · strength 0.18
  8. Peter J. Allen · 3 shared papers, 2015–2018 · strength 0.18
  9. Lilian Schwartz · 1 shared paper, 2025 · strength 0.16
  10. Julie Navez · 1 shared paper, 2025 · strength 0.16
  11. Jonathan Garnier · 1 shared paper, 2025 · strength 0.16
  12. Charles de Ponthaud · 1 shared paper, 2025 · strength 0.16
  13. Pierre‐Emmanuel Colombo · 1 shared paper, 2025 · strength 0.16
  14. Sébastien Gaujoux · 1 shared paper, 2025 · strength 0.16
  15. Francois-Regis Souche · 1 shared paper, 2025 · strength 0.16
  16. Emmanuel Buc · 1 shared paper, 2025 · strength 0.16
  17. Alain Sauvanet Sauvanet · 1 shared paper, 2025 · strength 0.16
  18. Ugo Marchèse · 1 shared paper, 2025 · strength 0.16
  19. Pietro Addeo Md · 1 shared paper, 2025 · strength 0.16
  20. Philippe Bachellier · 1 shared paper, 2025 · strength 0.16
  21. Mickaël Lesurtel · 1 shared paper, 2025 · strength 0.16
  22. Milena Muzzolini · 1 shared paper, 2025 · strength 0.16
  23. Christophe Laurent · 1 shared paper, 2025 · strength 0.16
  24. Richard Kinh Gian Do · 2 shared papers, 2015–2018 · strength 0.11
  25. Christelle d’Engremont · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.